Figure 3.

Combining protein vaccine with STING agonist delays TC-1 tumor growth and profoundly impacts tumor microenvironment. 10⁵ TC-1 cells were implanted subcutaneously on the back of C57BL/6 mice. When tumors were visible, mice were treated with two administrations of KISIMA vaccine, STING agonist or a combination of the two at one-week interval and tumor growth was monitored. (A) Vaccination schedule. Tumor growth (B) and median survival (C) were followed. CR, complete regression; ms, median survival. (D) 10 × 10 dot plot chart showing 100 circles, corresponding to 100%, and representing the proportion of different cell populations among CD45+ tumor-infiltrating cells; every circle represents 1% of the CD45+ population (see Figure S11 for gating strategy). (B) Pie chart representing different tumor infiltrating dendritic cell populations, moDCs (CD11b⁺MHCII^hiCD11c^hiLy6C⁺), cDC2 (CD11b⁺MHCII^hiCD11c^hiLy6C⁺CD103⁻), cDC1 (CD11b-MHCII^hiCD11c^hiCD24⁺ and CD103⁺ or CD8⁺), pDC (CD11b^-Ly6C⁺CD11c^intB220⁺PDCA1⁺). One representative of three experiments (n = 7/group/replicate) (B, C) or a pool of two experiments (n = 7/group) (D, E) are shown. Log-rank Mantel–Cox test, ***p < 0.001.